<DOC>
	<DOC>NCT00721916</DOC>
	<brief_summary>This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment of patients with metastatic colorectal cancer.</brief_summary>
	<brief_title>Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proved adenocarcinoma (colorectal cancer). Age: 20 â‰¤ at enrollment. No prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) to advanced disease. Patients who received adjuvant chemotherapy more than 180 days before enrollment can be allowed but those who received S1 or Oxaliplatin containing treatment shall be excluded. At least one measurable lesion by RECIST criteria Serious drug hypersensitivity. Prior history of peripheral neuropathy. Diarrhea . Simultaneously active double cancer.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>